Thalidomide alone or in combination with other agents for the treatment of myelodysplastic syndromes (MDS)

被引：2
|
作者：
Candoni, A.
Raza, A.
Galili, N.
Simeone, E.
Buttignol, S.
Silvestri, F.
Fanin, R.
机构：
[1] Univ Hosp, Div Hematol Bone Marrow Transplantat, Udine, Italy
[2] Univ Massachusetts, Med Ctr, Amherst, MA 01003 USA
来源：
LEUKEMIA RESEARCH | 2007年 / 31卷
关键词：
D O I：
10.1016/S0145-2126(07)70214-X
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S119 / S119
页数：1
相关论文
共 50 条
  • [1] Combination of thalidomide and Enbrel for the treatment of patients with myelodysplastic syndromes (MDS).
    Raza, A
    Dutt, D
    Lisak, L
    Dean, L
    Fantroy, L
    Gezer, S
    Syed, E
    Goldberg, C
    Loew, J
    Hsu, WT
    Venugopal, P
    BLOOD, 2001, 98 (11) : 273B - 274B
  • [2] Thalidomide as a single agent or in combination with topotecan, pentoxifylline and/or Enbrel in myelodysplastic syndromes (MDS).
    Raza, A
    Lisak, L
    Little, L
    Ekbal, M
    du Rant, M
    Ali, E
    Nascimben, F
    Tareen, M
    Venugopal, P
    BLOOD, 2000, 96 (11) : 146A - 146A
  • [3] Combination of thalidomide with pentoxifylline, ciprofloxacin, and dexamethasone (PCD) in patients with myelodysplastic syndromes (MDS).
    Raza, A
    Lisak, L
    Dutt, D
    Dean, L
    Fantroy, L
    Syed, E
    Gezer, S
    Hsu, WT
    Goldberg, C
    Loew, J
    Venugopal, P
    BLOOD, 2001, 98 (11) : 273B - 273B
  • [4] Combination of erythropoietin and thalidomide for the treatment of anemia in patients with myelodysplastic syndromes
    Musto, P
    Falcone, A
    Sanpaolo, G
    Bodenizza, C
    LEUKEMIA RESEARCH, 2006, 30 (04) : 385 - 388
  • [5] The Tolerability of Combination Therapy with Thalidomide and 5-Azacitidine in Patients with Advanced Myelodysplastic Syndromes (MDS).
    Kenealy, Melita K.
    Seymour, John F.
    Linda, Cowan
    Milner, Alvin
    Giri, Pratyush
    Ho, Shir-Jing
    Benson, Warwick
    Nicol, Andrew
    Campbell, Philip
    Prosser, Ian
    Underhill, Craig
    Cunningham, Ilona
    Mills, Anthony K.
    Szer, Jeffrey
    Presgrave, Peter
    Filshie, Robin
    BLOOD, 2009, 114 (22) : 695 - 695
  • [6] Improvement in cytopenias of patients with myelodysplastic syndromes (MDS) in response to thalidomide
    Raza, A
    Lisak, L
    Little, L
    Andrews, C
    Meyer, P
    Ekbal, M
    Venugopal, P
    EXPERIMENTAL HEMATOLOGY, 2000, 28 (07) : 103 - 104
  • [7] Venetoclax Combination with Hypomethylating Agents for Treatment of Myelodysplastic Syndromes
    Al Ali, Najla
    Sallman, David
    Nelson, Rebecca
    Talati, Chetasi
    Kuykendall, Andrew
    Sweet, Kendra
    Padron, Eric
    Lancet, Jeffrey
    List, Alan
    Komrokji, Rami
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S339 - S340
  • [8] Thalidomide for the treatment of patients with myelodysplastic syndromes
    Strupp, C
    Germing, U
    Aivado, M
    Misgeld, E
    Haas, R
    Gattermann, N
    LEUKEMIA, 2002, 16 (01) : 1 - 6
  • [9] Thalidomide for the treatment of patients with myelodysplastic syndromes
    C Strupp
    U Germing
    M Aivado
    E Misgeld
    R Haas
    N Gattermann
    Leukemia, 2002, 16 : 1 - 6
  • [10] Treatment of myelodysplastic syndromes with azacitidine and thalidomide
    Kenealy, M. K.
    Seymour, J. F.
    LEUKEMIA RESEARCH, 2007, 31 : S7 - S8
12345